YM150 is an orally active direct FXa inhibitor in clinical development. Proof of concept of YM150 was previously obtained in a dose escalation study, demonstrating a statistically significant dose-related trend in VTE prevention in patients undergoing total hip replacement (
Disclosure:Employment: G. Wetherill and L. Meems are emplyees of Astellas. Consultancy: All other authors: Received honoraria as Steering Committee member or Adjudication Committee member, and consultant from Astellas. Honoraria Information: Honoraria received from Astellas for above-mentioned tasks.